Does statin use improve pneumonia outcomes?

Chest

Volumn 136, Issue 5, 2009, Pages 1381-1388

  Chopra, Vineet ^a   Flanders, Scott A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; CERIVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTIOXIDANT ACTIVITY; BACTERIAL PNEUMONIA; CLINICAL TRIAL; DEVELOPED COUNTRY; DISEASE MARKER; DRUG BIOAVAILABILITY; DRUG COST; DRUG MECHANISM; DRUG USE; HEALTH CARE COST; HUMAN; IMMUNOMODULATION; INFLAMMATION; MORBIDITY; MORTALITY; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 70449337451     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.09-0941     Document Type: Article

References (48)

1. Terblanche M, Almog Y, Rosenson R, et al. Statins and sepsis: multiple modifications at multiple levels. Lancet Infect Dis 2007; 7:358-368 (Pubitemid 46590065)
2. Waldman A, Kritharides L. The pleiotropic effects of HMG-CoA reductase inhibitors: their role in osteoporosis and dementia. Drugs 2003; 63:139-152 (Pubitemid 36143341)
3. Chopra V, Choksi PU, Cavusoglu E. Beyond lipid lowering: the anti-hypertensive role of statins. Cardiovasc Drugs Ther 2007; 21:161-169 (Pubitemid 46817481)
4. Kruger P, Fitzsimmons K, Cook D, et al. Statin therapy is associated with fewer deaths in patients with bacteremia. Intensive Care Med 2006; 32:75-79 (Pubitemid 43039379)
5. Glynn RJ, Danielson E, Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; 360:1851-1856
6. Thomsen RW, Riis A, Norgaard M, et al. Rising incidence and persistently high mortality of hospitalized pneumonia: a 10-year population based study in Denmark. J Intern Med 2006; 259:410-417 (Pubitemid 43384232)
7. Wachter RM, Flanders SA, Fee C, et al. Public reporting of antibiotic timing in patients with pneumonia: lessons from a flawed performance measure. Ann Intern Med 2008; 149: 29-32 (Pubitemid 351931130)
8. Fry AM, Shay DK, Holman RC, et al. Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States: 1998-2002. JAMA 2005; 294:2712-2719
9. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343:425-430
10. Laufs U, Liao JK. Isoprenoid metabolism and the pleiotropic effects of statins. Curr Atheroscler Rep 2003; 5:372-378 (Pubitemid 38898896)
11. Patel TR, Corbett SA. Simvastatin suppresses LPS-induced Akt phosphorylation in the human monocyte cell line THP-1. J Surg Res 2004; 116:116-120
12. Chello M, Mastroroberto P, Patti G, et al. Simvastatin attenuates leukocyte-endothelial interactions after coronary revascularization with cardiopulmonary bypass. Heart 2003; 89:538-543 (Pubitemid 36520805)
13. Giusti-Paiva A, Martinez MR, Felix JV, et al. Simvastatin decreases nitric oxide overproduction and reverts the impaired vascular responsiveness induced by endotoxic shock in rates. Shock 2004; 21:271-275
14. Atunes G, Evans SA, Lordan JL, et al. Systemic cytokine levels in community-acquired pneumonia and their association with disease severity. Eur Respir J 2002; 20:990-995 (Pubitemid 35175139)
15. Chalmers JD, Singanayagam A, Hill A. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med 2008; 121:219-225 (Pubitemid 351317927)
16. Glynn P, Coakley R, Kilgallen I, et al. Circulating interleukin-6 and interleukin-10 in community acquired pneumonia. Thorax 1999; 54:51-55 (Pubitemid 29103752)
17. Fehr T, Kahlert C, Fierz W, et al. Statin-induced immunomodulatory effects on human T cells in vivo. Atherosclerosis 2004; 175:83-90 (Pubitemid 38746913)
18. Chan KY, Boucher ES, Gandhi PJ, et al. HMG-CoA reductase inhibitors for lowering elevated levels of C-reactive protein. Am J Health Syst Pharm 2004; 61:1676-1681 (Pubitemid 39481377)
19. Lobo SM, Lobo FR, Bota DP, et al. C-reactive protein levels correlate with mortality and organ failure in critically ill patients. Chest 2003; 123:2043-2049
20. Cowley HC, Bacon PJ, Goode HF, et al. Plasma antioxidant potential in severe sepsis: a comparison of survivors and non-survivors. Crit Care Med 1996; 24:1179-1183
21. Motoyama T, Okamoto K, Kukita I, et al. Possible role of increased oxidant stress in multiple organ failure after systemic inflammatory response syndrome. Crit Care Med 2003; 31:1048-1052 (Pubitemid 36444412)
22. Pleiner J, Schaller G, Mittermayer F, et al. Simvastatin prevents vascular hyporeactivity during inflammation. Circulation 2004; 110:3349-3354 (Pubitemid 39557498)
23. Grosser N, Erdmann K, Hemmerle A, et al. Rosuvastatin upregulates the antioxidant defense protein heme oxygenase-1. Biochem Biophys Res Commun 2004; 325:871-876 (Pubitemid 39487953)
24. Veillard NR, Braunersreuther V, Arnaud C, et al. Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis 2006; 188:51-58 (Pubitemid 44142533)
25. Diomede L, Albani D, Sottocorno M, et al. In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol 2001; 21: 1327-1332
26. Kothe H, Dalhoff K, Rupp J, et al. Hydroxymethyglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation 2000; 101: 1760-1763 (Pubitemid 30213094)
27. Pruefer D, Scalia R, Lefer AM. Simvastatin inhibits leukocyte endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arterioscler Thromb Vasc Biol 1999; 19:2894-2900 (Pubitemid 30029815)
28. Weber C, Erl W, Weber KS, et al. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997; 30:1212-1217 (Pubitemid 27501437)
29. Madonna R, DiNapoli P, Massaro M, et al. Simvastatin attenuates expression of cytokine-inducible nitric oxide synthase in embryonic cardiac myoblasts. J Biol Chem 2005; 280:13503-13511 (Pubitemid 40517241)
30. Kallen J, Welzenbach K, Ramage P, et al. Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain. J Mol Biol 1999; 292:1-9 (Pubitemid 29425648)
31. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7:687-692 (Pubitemid 32588024)
32. Jacobson JR, Barnard JW, Grigoryev DN, et al. Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am J Physiol Lung Cell Mol Physiol 2005; 288:1026-1032
33. Jerwood S, Cohen J. Unexpected antimicrobial effect of statins. J Antimicrob Chemother 2008; 61:362-364
34. Pentikainen PJ, Saraheimo M, Schwartz JI, et al. Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans. J Clin Pharmacol 1992; 32:136-140
35. Goode HF, Cowley HC, Walker BE, et al. Decreased antioxidant status and increased lipid peroxidation in patients with septic shock and secondary organ dysfunction. Crit Care Med 1995; 23:646-651
36. Fischetti F, Caretta R, Borotto G, et al. Fluvastatin treatment inhibits leukocyte adhesion and extravasation in models of complement-mediated acute inflammation. Clin Exp Immunol 2004; 135:186-193 (Pubitemid 38177955)
37. Naidu BV, Wooley SM, Farivar AS, et al. Simvastatin ameliorates injury in an experimental model of lung ischemia-reperfusion. J Thorac Cardiovasc Surg 2003; 126:482-489 (Pubitemid 37048516)
38. Fessler MB, Young SK, Jeyaseelan S, et al. A role for hydroxy-methylglutaryl coenzyme A reductase in pulmonary inflammation and host defense. Am J Respir Crit Care Med 2005; 171:606-615 (Pubitemid 40365416)
39. Mortensen EM, Restrepo MI, Anzueto A, et al. The effect of prior statin use on 30-day mortality for patients hospitalized with community acquired pneumonia. Respir Res 2005; 6:82-89 (Pubitemid 41410154)
40. Frost FJ, Petersen H, Tollestrup K, et al. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007; 131:1006-1012 (Pubitemid 46608700)
41. Van de Garde EMW, Hak E, Spuverein PC, et al. Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax 2006; 61:957-961 (Pubitemid 44787165)
42. Mortensen EM, Pugh MJ, Copeland LA, et al. Impact of statins and angiotensin-converting enzyme inhibitors on morality of subjects hospitalized with pneumonia. Eur Respir J 2008; 31:611-617
43. Schlienger RG, Fedson D, Jick SS, et al. Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacotherapy 2007; 27:325-332 (Pubitemid 46327900)
44. Thomsen RW, Riis A, Kornum J, et al. Preadmission use of statins and outcomes after hospitalization with pneumonia: population based cohort study of 29,900 patients. Arch Intern Med 2008; 168:2081-2087
45. Chalmers JD, Singanayagam A, Murray MP, et al. Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med 2008; 121:1002-1007
46. Majumdar SR, McAlister FA, Eurich DT, et al. Statins and outcomes in patients admitted to hospital with community-acquired pneumonia: population based prospective cohort study. BMJ 2006; 333:999
47. Glynn RJ, Schneeweiss S, Wang PS, et al. Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. J Clin Epidemiol 2006; 59:819-828 (Pubitemid 44040877)
48. Thomsen RW, Johnsen SP, Olesen AV, et al. Socioeconomic gradient in the use of statins among Danish patients: population-based cross-sectional study. Br J Clin Pharmacol 2005; 6:534-542